Gene therapy for pancreatic cancer

Surgical Oncology Clinics of North America

Volumn 11, Issue 3, 2002, Pages 537-569

  Tseng, Jennifer F ^a,b   Mulligan, Richard C ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANGIOSTATIN; BETA INTERFERON; CA 19-9 ANTIGEN; CA 242 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOSINE DEAMINASE; ENDOSTATIN; FLUCYTOSINE; GANCICLOVIR; GENE PRODUCT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 4; MUCIN 1; NEU DIFFERENTIATION FACTOR; ONYX 015; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN KINASE C ALPHA; PROTEIN P16; PROTEIN P21; PROTEIN P53; SMAD PROTEIN; THROMBOSPONDIN 1; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BIOENGINEERING; CANCER CLASSIFICATION; CANCER IMMUNOTHERAPY; GENE AMPLIFICATION; GENE DELIVERY SYSTEM; GENE TECHNOLOGY; GENE THERAPY; GENE TRANSFER; HUMAN; IMMUNOLOGY; MOLECULAR BIOLOGY; MOLECULAR GENETICS; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; STEM CELL; TREATMENT INDICATION; VIROLOGY;

ADENOCARCINOMA; CANCER VACCINES; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; FORECASTING; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, TUMOR SUPPRESSOR; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; PANCREATIC NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS; TRANSDUCTION, GENETIC; TREATMENT OUTCOME; UNITED STATES;

EID: 0036660648     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1055-3207(02)00023-6     Document Type: Review

References (259)

1. Greenlee RT, Hill-Harmon MB, Murray T, et al. Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36.
2. Lieberman SM, Horig H, Kaufman HL. Innovative treatments for pancreatic cancer. Surg Clin North Am 2001;81:715-39.
3. van Riel JM, van Groeningen CJ, Pinedo HM, et al. Current chemotherapeutic possibilities in pancreaticobiliary cancer. Ann Oncol 1999;10(Suppl 4):157-61.
4. Warshaw AL, Fernandez-del Castillo C. Pancreatic carcinoma. N Engl J Med 1992;326:455-65.
5. Jaffee EM. Immunotherapy of cancer. Ann NY Acad Sci 1999;886:67-72.
6. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting antitumor immunity. Proc Natl Acad Sci USA 1993;90:3539-43.
7. Jaffee EM, Hruban RH, Biedrzycki B, et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: A phase I trial of safety and immune activation. J Clin Oncol 2001;19:145-56.
8. Simons JW, Jaffee EM, Weber CE, et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 1997;57:1537-46.
9. Boczkowski D, Nair SK, Nam JH, et al. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res 2000;60:1028-34.
10. Klein C, Bueler H, Mulligan RC. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines. J Exp Med 2000;191:1699-708.
11. Ribas A, Butterfield LH, McBride WH, et al. Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells. Cancer Res 1997;57:2865-9.
12. Tsang KY, Zhu M, Even J, et al. The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells. Cancer Res 2001;61:7568-76.
13. Wiltrout RH, Gregorio TA, Fenton RG, et al. Cellular and molecular studies in the treatment of murine renal cancer. Semin Oncol 1995;22:9-16.
14. Zitvogel L, Tahara H, Robbins PD, et al. Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts. J Immunol 1995;155:1393-403.
15. Bernards R, Destree A, McKenzie S, et al. Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector. Proc Natl Acad Sci USA 1987;84:6854-8.
16. Earl PL, Moss B, Morrison RP, et al. T-lymphocyte priming and protection against Friend leukemia by vaccinia-retrovirus env gene recombinant. Science 1986;234:728-31.
17. Sawada Y, Urbanelli D, Raskova J, et al. Adenovirus tumor-specific transplantation antigen is a function of the E1A early region. J Exp Med 1986;163:563-72.
18. Tanaka K, Hayashi H, Hamada C, et al. Expression of major histocompatibility complex class I antigens as a strategy for the potentiation of immune recognition of tumor cells. Proc Natl Acad Sci USA 1986;83:8723-7.
19. Altenschmidt U, Kahl R, Moritz D, et al. Cytolysis of tumor cells expressing the Neu/erbB-2, erbB-3, and erbB-4 receptors by genetically targeted naive T lymphocytes. Clin Cancer Res 1996;2:1001-8.
20. Gross G, Eshhar Z. Endowing T cells with antibody specificity using chimeric T cell receptors. FASEB J 1992;6:3370-8.
21. Hwu P, Yang JC, Cowherd R, et al. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res 1995;55:3369-73.
22. Moritz D, Wels W, Mattern J, et al. Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. Proc Natl Acad Sci USA 1994;91:4318-22.
23. Slavin-Chiorini DC, Kashmiri SV, Schlom J, et al. Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins. Cancer Res 1995;55:5957s-67s.
24. Jaffee EM, Pardoll DM. Considerations for the clinical development of cytokine gene-transduced tumor cell vaccines. Methods 1997;12:143-53.
25. Jaffee EM, Schutte M, Gossett J, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J Sci Am 1998;4:194-203.
26. Jimenez RE, Warshaw AL, Rattner DW, et al. Impact of laparoscopic staging in the treatment of pancreatic cancer. Arch Surg 2000;135:409-14.
27. Brouwenstijn N, Hoogstraten C, Verdegaal EM, et al. Definition of unique and shared T-cell defined tumor antigens in human renal cell carcinoma. J Immunother 1998;21:427-34.
28. Ludewig B, Ochsenbein AF, Odermatt B, et al. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J Exp Med 2000;191:795-804.
29. Borrello I, Sotomayor EM, Cooke S, et al. A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines. Hum Gene Ther 1999;10:1983-91.
30. Ambe K, Mori M, Enjoji M. S-100 protein-positive dendritic cells in colorectal adenocarcinomas. Distribution and relation to the clinical prognosis. Cancer 1989;63:496-503.
31. Celluzzi CM, Mayordomo JI, Storkus WJ, et al. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med 1996;183:283-7.
32. Cohen DA, Kaplan AM. Adherent Ia+ murine cell lines with characteristics of dendritic cells. II. Characteristics of I region-restricted antigen presentation. Cell Immunol 1983;80:349-62.
33. Cohen PA, Cohen PJ, Rosenberg SA, et al. CD4+ T-cells from mice immunized to syngeneic sarcomas recognize distinct, non-shared tumor antigens. Cancer Res 1994;54:1055-8.
34. Flamand V, Sornasse T, Thielemans K, et al. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur J Immunol 1994;24:605-10.
35. Gabrilovich DI, Nadaf S, Corak J, et al. Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors. Cell Immunol 1996;170:111-9.
36. Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995;1:1297-302.
37. Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines. Stem Cells 1997;15:94-103.
38. Zitvogel L, Mayordomo JI, Tjandrawan T, et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell l-associated cytokines. J Exp Med 1996;183:87-97.
39. Schnurr M, Galambos P, Scholz C, et al. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: An in vitro model for the assessment of tumor vaccines. Cancer Res 2001;61:6445-50.
40. Schott M, Feldkamp J, Lettmann M, et al. Dendritic cell immunotherapy in a neuroendocrine pancreas carcinoma. Clin Endocrinol (Oxf) 2001;55:271-7.
41. Marten A, Ziske C, Schottker B, et al. Increase in the immunostimulatory effect of dendritic cells by pulsing with serum derived from pancreatic and colorectal cancer patients. Int J Colorectal Dis 2000;15:197-205.
42. Alters SE, Gadea JR, Philip R. Immunotherapy of cancer. Generation of CEA specific CTL using CEA peptide pulsed dendritic cells. Adv Exp Med Biol 1997;417:519-24.
43. Brossart P, Heinrich KS, Stuhler G, et al. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 1999;93:4309-17.
44. Marten A, Schottker B, Ziske C, et al. Increase of the immunostimulatory effect of dendritic cells by pulsing with CA 19-9 protein. J Immunother 2000;23:464-72.
45. Peiper M, Goedegebuure PS, Eberlein TJ. Generation of peptide-specific cytotoxic T lymphocytes using allogeneic dendritic cells capable of lysing human pancreatic cancer cells. Surgery 1997;122:235-42.
46. Gjertsen MK, Bakka A, Breivik J, et al. Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: Results of a phase I/II study. Int J Cancer 1996;65:450-3.
47. Gong J, Chen D, Kashiwaba M, et al. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 1997;3:558-61.
48. Gong J, Chen D, Kashiwaba M, et al. Reversal of tolerance to human MUC1 antigen in MUCI transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc Natl Acad Sci USA 1998;95:6279-83.
49. Li J, Holmes LM, Franek KJ, et al. Purified hybrid cells from dendritic cell and tumor cell fusions are superior activators of antitumor immunity. Cancer Immunol Immunother 2001;50:456-62.
50. Gong J, Avigan D, Chen D, et al. Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc Natl Acad Sci USA 2000;97:2715-8.
51. Kugler A, Stuhler G, Walden P, et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 2000;6:332-6.
52. Curiel-Lewandrowski C, Mahnke K, Labeur M, et al. Transfection of immature murine bone marrow-derived dendritic cells with the granulocyte-macrophage colony-stimulating factor gene potently enhances their in vivo antigen-presenting capacity. J Immunol 1999;163:174-83.
53. Diao J, Smythe JA, Smyth C, et al. Human PBMC-derived dendritic cells transduced with an adenovirus vector induce cytotoxic T-lymphocyte responses against a vector-encoded antigen in vitro. Gene Ther 1999;6:845-53.
54. Philip R, Alters SE, Brunette E, et al. Dendritic cells loaded with MART-1 peptide or infected with adenoviral construct are functionally equivalent in the induction of tumor-specific cytotoxic T lymphocyte responses in patients with melanoma. J Immunother 2000;23:168-76.
55. Brown M, Zhang Y, Dermine S, et al. Dendritic cells infected with recombinant fowlpox virus vectors are potent and long-acting stimulators of transgene-specific class I restricted T lymphocyte activity. Gene Ther 2000;7:1680-9.
56. Gahn B, Siller-Lopez F, Pirooz AD, et al. Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: A potential treatment strategy for Epstein-Barr virus-positive Hodgkin's lymphoma. Int J Cancer 2001;93:706-13.
57. Kikuchi T, Moore MA, Crystal RG. Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors. Blood 2000;96:91-9.
58. Lohmann S, Galle K, Knop J, et al. CD83+ human dendritic cells transfected with tumor peptide cDNA by electroporation induce specific T-cell responses: A potential tool for gene immunotherapy. Cancer Gene Ther 2000;7:605-14.
59. Miller PW, Sharma S, Stolina M, et al. Intratumoral administration of adenoviral interleukin 7 gene-modified dendritic cells augments specific antitumor immunity and achieves tumor eradication. Hum Gene Ther 2000;11:53-65.
60. Rughetti A, Biffoni M, Sabbatucci M, et al. Transfected human dendritic cells to induce antitumor immunity. Gene Ther 2000;7:1458-66.
61. Song W, Tong Y, Carpenter H, et al. Persistent, antigen-specific, therapeutic antitumor immunity by dendritic cells genetically modified with an adenoviral vector to express a model tumor antigen. Gene Ther 2000;7:2080-6.
62. Chaux P, Luiten R, Demotte N, et al. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1. J Immunol 1999;163:2928-36.
63. Movassagh M, Baillou C, Cosset FL, et al. High level of retrovirus-mediated gene transfer into dendritic cells derived from cord blood and mobilized peripheral blood CD34+ cells. Hum Gene Ther 1999;10:175-87.
64. Qin Z, Noffz G, Mohaupt M, et al. Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colony-stimulating factor gene-modified tumor cells. J Immunol 1997;159:770-6.
65. Tillman BW, Hayes TL, DeGruijl TD, et al. Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model. Cancer Res 2000;60:5456-63.
66. Metharom P, Ellem KA, Schmidt C, et al. Lentiviral vector-mediated tyrosinase-related protein 2 gene transfer to dendritic cells for the therapy of melanoma. Hum Gene Ther 2001;12:2203-13.
67. Trevor KT, Hersh EM, Brailey J, et al. Transduction of human dendritic cells with a recombinant modified vaccinia Ankara virus encoding MUC1 and IL-2. Cancer Immunol Immunother 2001;50:397-407.
68. Pecher G, Spahn G, Schirrmann T, et al. Mucin gene (MUC1) transfer into human dendritic cells by cationic liposomes and recombinant adenovirus. Anticancer Res 2001;21:2591-6.
69. Ziske C, Marten A, Schottker B, et al. Resistance of pancreatic carcinoma cells is reversed by coculturing NK-like T cells with dendritic cells pulsed with tumor-derived RNA and CA 19-9. Mol Ther 2001:3:54-60.
70. Tseng JF, Mulligan RC. Dendritic cells expressing K-ras inhibit murine pancreatic adenocarcinoma tumor growth in vivo. Surg Forum 2001;LII:284-5.
71. Hruban RH, Iacobuzio-Donahue C, Wilentz RE, et al. Molecular pathology of pancreatic cancer. Cancer J 2001;7:251-8.
72. Jaffee EM, Pardoll DM. Murine tumor antigens: Is it worth the search? Curr Opin Immunol 1996;8:622-7.
73. Laheru D, Biedrzycki B, Jaffee EM. Immunologic approaches to the management of pancreatic cancer. Cancer J 2001;7:324-37.
74. Kahn S, Yamamoto F, Almoguera C, et al. The c-K-ras gene and human cancer. Anticancer Res 1987;7:639-52.
75. Almoguera C, Shibata D, Forrester K, et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988;53:549-54.
76. Smit VT, Boot AJ, Smits AM, et al. KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res 1988;16:7773-82.
77. Gedde-Dahl TD, Olsen BH, Thorsby E, et al. Oncogene-derived peptides: A new class of tumor rejection antigens? Transplant Proc 1993;25:1385-6.
78. Gjertsen MK, Bakka A, Breivik J, et al. Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation. Lancet 1995;346:1399-400.
79. Gjertsen MK, Bjorheim J, Saeterdal I, et al. Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation. Int J Cancer 1997;72:784-90.
80. Gjertsen MK, Saeterdal I, Thorsby E, et al. Characterisation of immune responses in pancreatic carcinoma patients after mutant p21 ras peptide vaccination. Br J Cancer 1996;74:1828-33.
81. Abrams SI, Khleif SN, Bergmann-Leitner ES, et al. Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations. Cell Immunol 1997;182:137-51.
82. Khleif SN, Abrams SI, Hamilton JM, et al. A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors. J Immunother 1999;22:155-65.
83. Gabrilovich DI, Cunningham HT, Carbone DP. IL-12 and mutant P53 peptide-pulsed dendritic cells for the specific immunotherapy of cancer. J Immunother Emphasis Tumor Immunol 1996;19:414-8.
84. Ishida T, Chada S, Stipanov M, et al. Dendritic cells transduced with wild-type p53 gene elicit potent anti tumour immune responses. Clin Exp Immunol 1999; 117:244-51.
85. Nikitina EY, Clark JI, Van Beynen J, et al. Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients. Clin Cancer Res 2001;7:127-35.
86. Rudert F, Saunders AM, Rebstock S, et al. Characterization of murine carcinoembryonic antigen gene family members. Mamm Genome 1992;3:262-73.
87. Thompson JA, Grunert F, Zimmermann W. Carcinoembryonic antigen gene family: Molecular biology and clinical perspectives. J Clin Lab Anal 1991;5:344-66.
88. Kantor J, Irvine K, Abrams S, et al. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J Natl Cancer Inst 1992;84:1084-91.
89. Kantor J, Irvine K, Abrams S, et al. Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate. Cancer Res 1992;52:6917-25.
90. Kaufman H, Schlom J, Kantor J. A recombinant vaccinia virus expressing human carcinoembryonic antigen (CEA). Int J Cancer 1991;48:900-7.
91. Conry RM, Khazaeli MB, Saleh MN, et al. Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: Comparison of intradermal versus subcutaneous administration. Clin Cancer Res 1999;5:2330-7.
92. McAneny D, Ryan CA, Beazley RM, et al. Results of a phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer. Ann Surg Oncol 1996;3:495-500.
93. Tsang KY, Zaremba S, Nieroda CA, et al. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 1995;87:982-90.
94. Marshall JL, Hoyer RJ, Toomey MA, et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anticarcinoembryonic antigen immune responses. J Clin Oncol 2000;18:3964-73.
95. Horig H, Lee DS, Conkright W, et al. Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol Immunother 2000;49:504-14.
96. Nolan KF, Yun CO, Akamatsu Y, et al. Bypassing immunization: Optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA. Clin Cancer Res 1999;5:3928-41.
97. Nair SK, Boczkowski D, Morse M, et al. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat Biotechnol 1998;16:364-9.
98. Nair SK, Hull S, Coleman D, et al. Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA. Int J Cancer 1999;82:121-4.
99. Morse MA, Deng Y, Coleman D, et al. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res 1999;5:1331-8.
100. Clary BM, Lyerly HK. Gene therapy and pancreatic cancer. Surg Oncol Clin N Am 1998;7:217-49.
101. Ho JJ. Mucins in the diagnosis and therapy of pancreatic cancer. Curr Pharm Des 2000;6:1881-96.
102. Mukherjee P, Ginardi AR, Madsen CS, et al. Mice with spontaneous pancreatic cancer naturally develop MUC-1-specific CTLs that eradicate tumors when adoptively transferred. J Immunol 2000;165:3451-60.
103. Koido S, Tanaka Y, Chen D, et al. The kinetics of in vivo priming of CD4 and CD8 T cells by dendritic/tumor fusion cells in MUC1-transgenic mice. J Immunol 2002;8:2111-7.
104. Tanaka Y, Koido S, Chen D, et al. Vaccination with allogeneic dendritic cells fused to carcinoma cells induces antitumor immunity in MUC1 transgenic mice. Clin Immunol 2001;101:192-200.
105. Dugan MC, Sarkar FH. Current concepts in pancreatic cancer: Symposium summary. Pancreas 1998;17:325-33.
106. Friess H, Yamanaka Y, Kobrin MS, et al. Enhanced erbB-3 expression in human pancreatic cancer correlates with tumor progression. Clin Cancer Res 1995;1:1413-20.
107. Sakorafas GH, Tsiotou AG, Tsiotos GG. Molecular biology of pancreatic cancer; oncogenes, tumour suppressor genes, growth factors, and their receptors from a clinical perspective. Cancer Treat Rev 2000;26:29-52.
108. Friess H, Kleeff J, Korc M, et al. Molecular aspects of pancreatic cancer and future perspectives. Dig Surg 1999;16:281-90.
109. Brossart P, Stuhler G, Flad T, et al. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res 1998;58:732-6.
110. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275:1943-7.
111. Podsypanina K, Ellenson LH, Nemes A, et al. Mutation of Pten/Mmacl in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA 1999;96:1563-8.
112. Steck PA, Pershouse MA, Jasser SA, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997;15:356-62.
113. Okami K, Wu L, Riggins G, et al. Analysis of PTEN/MMAC 1 alterations in aerodigestive tract tumors. Cancer Res 1998;58:509-11.
114. Cheng JQ, Godwin AK, Bellacosa A, et al. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci USA 1992;89:9267-71.
115. Cheng JQ, Ruggeri B, Klein WM, et al. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci USA 1996;93:3636-41.
116. Schwarte-Waldhoff I, Volpert OV, Bouck NP, et al. Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. Proc Natl Acad Sci USA 2000;97:9624-9.
117. Barbera VM, Martin M, Marinoso L, et al. The 18q21 region in colorectal and pancreatic cancer: Independent loss of DCC and DPC4 expression. Biochim Biophys Acta 2000;1502:283-96.
118. Hahn SA, Schutte M, Hoque AT, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996;271:350-3.
119. Kelley JR, Brown JM, Frasier MM, et al. The cancer-associated Sm-like oncogene: A novel target for the gene therapy of pancreatic cancer. Surgery 2000;128:353-60.
120. Kelley JR, Fraser MM, Schweinfest CW, et al. CaSm/gemcitabine chemo-gene therapy leads to prolonged survival in a murine model of pancreatic cancer. Surgery 2001;130:280-8.
121. Hombach A, Sircar R, Heuser C, et al. Chimeric antiTAG72 receptors with immunoglobulin constant Fc domains and gamma or zeta signalling chains. Int J Mol Med 1998;2:99-103.
122. Fritsche Jr. HA, Gelder FB. Serum tumor markers for pancreatic carcinoma. Immunol Ser 1990;53:289-96.
123. Takasaki H, Tempero MA, Uchida E, et al. Comparative studies on the expression of tumor-associated glycoprotein (TAG-72), CA 19-9 and DU-PAN-2 in normal, benign and malignant pancreatic tissue. Int J Cancer 1988;42:681-6.
124. Tempero M, Takasaki H, Uchida E, et al. Co-expression of CA 19-9, DU-PAN-2, CA 125, and TAG-72 in pancreatic adenocarcinoma. Am J Surg Pathol 1989;13:89-95
125. Knapp ML. Partial characterisation of an oncofetal pancreatic antigen. Its role in the differential diagnosis and therapy of patients with pancreatic cancer. Ann Clin Biochem 1981;18:131-42.
126. Gelder F, Reese C, Moossa AR, et al. Studies on an oncofetal antigen. POA. Cancer 1978;42:1635-45.
127. Oguchi H, Homma T, Kawa S, et al. A pancreatic oncofetal antigen (POA): Its characterization and application for enzyme immunoassay. Cancer Detect Prev 1984;7:51-8.
128. Maruyama H, Mori T, Shimano T, et al. Differential distribution of the pancreatic cancer-associated antigen (PCAA) and pancreatic tissue antigen (PaA) in pancreatic and gastrointestinal cancer tissues. Ann N Y Acad Sci 1983;417:240-50.
129. Shimano T, Mori T, Kitada M, et al. Purification and characterization of a pancreatic cancer-associated antigen (PCAA) from normal colonic mucosa. Ann N Y Acad Sci 1983;417:97-104.
130. Schultze JL, Vonderheide RH. From cancer genomics to cancer immunotherapy: Toward second-generation tumor antigens. Trends Immunol 2001;22:516-23.
131. Le Naour F, Misek DE, Krause MC, et al. Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer. Clin Cancer Res 2001;7:3328-35.
132. Meehan KL, Holland JW, Dawkins HJ. Proteomic analysis of normal and malignant prostate tissue to identify novel proteins lost in cancer. Prostate 2002;50:54-63.
133. Mills GB, Bast Jr. RC, Srivastava S. Future for ovarian cancer screening: Novel markers from emerging technologies of transcriptional profiling and proteomics. J Natl Cancer Inst 2001;93:1437-9.
134. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572-7.
135. Brichory F, Beer D, Le Naour F, et al. Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer. Cancer Res 2001;61:7908-12.
136. Klade CS, Voss T, Krystek E, et al. Identification of tumor antigens in renal cell carcinoma by serological proteome analysis. Proteomics 2001;1:890-8.
137. Ryu B, Jones J, Blades NJ, et al. Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression. Cancer Res 2002;62:819-26.
138. Jaffee EM, Thomas MC, Huang AY, et al. Enhanced immune priming with spatial distribution of paracrine cytokine vaccines. J Immunother Emphasis Tumor Immunol 1996;19:176-83.
139. Clary BM, Coveney EC, Philip R, et al. Inhibition of established pancreatic cancers following specific active immunotherapy with interleukin-2 gene-transduced tumor cells. Cancer Gene Ther 1997;4:97-104.
140. Kimura M, Tagawa M, Takenaga K, et al. Loss of tumorigenicity of human pancreatic carcinoma cells engineered to produce interleukin-2 or interleukin-4 in nude mice: a potentiality for cancer gene therapy. Cancer Lett 1998;128:47-53.
141. Kimura M, Yoshida Y, Narita M, et al. Acquired immunity in nude mice induced by expression of the IL-2 or IL-4 gene in human pancreatic carcinoma cells and antitumor effect generated by in vivo gene transfer using retrovirus. Int J Cancer 1999;82:549-55.
142. Yoshida Y, Tasaki K, Kimurai M, et al. Antitumor effect of human pancreatic cancer cells transduced with cytokine genes which activate Th1 helper T cells. Anticancer Res 1998;18:333-5.
143. Yoshida Y, Tasaki K, Miyauchi M, et al. Impaired tumorigenicity of human pancreatic cancer cells retrovirally transduced with interleukin-12 or interleukin-15 gene. Cancer Gene Ther 2000;7:324-31.
144. David AK, Vaughn DJ, Holroyde CP, et al. A phase II trial of 5-fluorouracil, leucovorin, and interferon alpha 2A (IFN-alpha 2a) in metastatic pancreatic carcinoma: A Penn Cancer Clinical Trials Group (PCCTG) trial. Am J Clin Oncol 2000;23:37-9.
145. Riecken EO, Rosewicz S. Retinoids in pancreatic cancer. Ann Oncol 1999;10:197-200.
146. Sporn JR, Buzaid AC, Slater D, et al. Treatment of advanced pancreatic adenocarcinoma with 5-FU, leucovorin, interferon-alpha-2b, and cisplatin. Am J Clin Oncol 1997;20:81-3.
147. Heufler C, Koch F, Schuler G. Granulocyte/macrophage colony-stimulating factor and interleukin 1 mediate the maturation of murine epidermal Langerhans cells into potent immunostimulatory dendritic cells. J Exp Med 1988;167:700-5.
148. Markowicz S, Engleman EG. Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro. J Clin Invest 1990;85:955-61.
149. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994;179:1109-18.
150. Levitsky HI, Montgomery J, Ahmadzadeh M, et al. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. J Immunol 1996;156:3858-65.
151. Thomas MC, Greten TF, Pardoll DM, et al. Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine. Hum Gene Ther 1998;9:835-43.
152. Kimura M, Tagawa M, Yoshida Y, et al. Impaired in vivo tumor growth of human pancreatic carcinoma cells retrovirally transduced with GM-CSF gene. Anticancer Res 1998;18:165-70.
153. Ogawa T, Kusumoto M, Mizumoto K, et al. GM-CSF gene therapy using adenoviral vector in hamster pancreatic cancer. J Hepatobiliary Pancreat Surg 2000;7:306-11.
154. Berns AJ, Clift S, Cohen LK, et al. Phase I study of non-replicating autologous tumor cell injections using cells prepared with or without GM-CSF gene transduction in patients with metastatic renal cell carcinoma. Hum Gene Ther 1995;6:347-68.
155. Loudon PT, Blakeley DM, Boursnell ME, et al. Preclinical safety testing of DISC-hGMCSF to support phase I clinical trials in cancer patients. J Gene Med 2001;3:458-67.
156. Ryan CW, Vogelzang NJ, Dumas MC, et al. Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: Results of two phase II clinical trials. Cancer 2000;88:1317-24.
157. Hurwitz AA, Foster BA, Kwon ED, et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 2000;60:2444-8.
158. Hurwitz AA, Sullivan TJ, Krummel MF, et al. Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis. J Neuroimmunol 1997;73:57-62.
159. Hurwitz AA, Yu TF, Leach DR, et al. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci USA 1998;95:10067-71.
160. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;271:1734-6.
161. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971;285:1182-6.
162. Kong HL, Crystal RG. Gene therapy strategies for tumor antiangiogenesis. J Natl Cancer Inst 1998;90:273-86.
163. Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996;380:439-42.
164. Kong HL, Hecht D, Song W, et al. Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor. Hum Gene Ther 1998;9:823-33.
165. Millauer B, Longhi MP, Plate KH, et al. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res 1996;56:1615-20.
166. Strawn LM, McMahon G, App H, et al. Flk-1 as a target for tumor growth inhibition. Cancer Res 1996;56:3540-5.
167. Warren RS, Yuan H, Matli MR, et al. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 1995;95:1789-97.
168. Kampfer H, Pfeilschifter J, Frank S. Expressional regulation of angiopoietin-1 and -2 and the tie-1 and -2 receptor tyrosine kinases during cutaneous wound healing: A comparative study of normal and impaired repair. Lab Invest 2001;81:361-73.
169. Sato TN, Qin Y, Kozak CA, et al. Tie-1 and tie-2 define another class of putative receptor tyrosine kinase genes expressed in early embryonic vascular system. Proc Natl Acad Sci USA 1993;90:9355-8.
170. Siemeister G, Schirner M, Weindel K, et al. Two independent mechanisms essential for tumor angiogenesis: Inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway. Cancer Res 1999;59:3185-91.
171. Theurillat JP, Hainfellner J, Maddalena A, et al. Early induction of angiogenetic signals in gliomas of GFAP-v-src transgenic mice. Am J Pathol 1999;154:581-90.
172. Bagheri-Yarmand R, Kourbali Y, Mabilat C, et al. The suppression of fibroblast growth factor 2/fibroblast growth factor 4-dependent tumour angiogenesis and growth by the antigrowth factor activity of dextran derivative (CMDB7). Br J Cancer 1998;78:111-8.
173. Ebert MP, Hernberg S, Fei G, et al. Induction and expression of cyclin D3 in human pancreatic cancer. J Cancer Res Clin Oncol 2001;127:449-54.
174. Szepeshazi K, Halmos G, Schally AV, et al. Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogs. J Cancer Res Clin Oncol 1999;125:444-52.
175. Davidoff AM, Leary MA, Ng CY, et al. Gene therapy-mediated expression by tumor cells of the angiogenesis inhibitor flk-1 results in inhibition of neuroblastoma growth in vivo. J Pediatr Surg 2001;36:30-6.
176. Hasan J, Jayson GC. VEGF antagonists. Expert Opin Biol Ther 2001;1:703-18.
177. Lin P, Buxton JA, Acheson A, et al. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc Natl Acad Sci USA 1998;95:8829-34.
178. Mori A, Arii S, Furutani M, et al. Soluble Flt-1 gene therapy for peritoneal metastases using HVJ-cationic liposomes. Gene Ther 2000;7:1027-33.
179. Rowland-Goldsmith MA, Maruyama H, Kusama T, et al. Soluble type II transforming growth factor-beta (TGF-beta) receptor inhibits TGF-beta signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation. Clin Cancer Res 2001;7:2931-40.
180. Chiarugi V, Magnelli L, Gallo O. Cox-2, iNOS and p53 as play-makers of tumor angiogenesis. Int J Mol Med 1998;2:715-9.
181. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-85.
182. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: A circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth. Cold Spring Harb Symp Quant Biol 1994;59:471-82.
183. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma.Cell 1994;79:315-28.
184. Berger AC, Alexander HR, Tang G, et al. Endothelial monocyte activating polypeptide II induces endothelial cell apoptosis and may inhibit tumor angiogenesis. Microvasc Res 2000;60:70-80.
185. Berger AC, Tang G, Alexander HR, et al. Endothelial monocyte-activating polypeptide II, a tumor-derived cytokine that plays an important role in inflammation, apoptosis, and angiogenesis. J Immunother 2000;23:519-27.
186. Jackson D, Volpert OV, Bouck N, et al. Stimulation and inhibition of angiogenesis by placental proliferin and proliferin-related protein. Science 1994;266:1581-4.
187. Kuo CJ, Farnebo F, Yu EY, et al. Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc Natl Acad Sci USA 2001;98:4605-10.
188. Tseng JF, Farnebo FA, Kisker O, et al. Adenovirus-mediated delivery of a soluble form of the VEGF receptor Flk1 delays the growth of murine and human pancreatic adenocarcinoma in mice. Surg 2002, in press.
189. Niederman TMJ, Ghogawala Z, Carter BS, et al. Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors. Proc Natl Acad Sci USA 2002, in press.
190. Licht T, Gottesman MM, Pastan I. Transfer of the MDRI (multidrug resistance) gene: Protection of hematopoietic cells from cytotoxic chemotherapy, and selection of transduced cells in vivo. Cytokines Mol Ther 1995;1:11-20.
191. Mickisch GH, Aksentijevich I, Schoenlein PV, et al. Transplantation of bone marrow cells from transgenic mice expressing the human MDR1 gene results in long-term protection against the myelosuppressive effect of chemotherapy in mice. Blood 1992;79:1087-93.
192. Ueda K, Cardarelli C, Gottesman MM, et al. Expression of a full-length cDNA for the human "MDRI" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA 1987;84:3004-8.
193. Allay JA, Galipeau J, Blakley RL, et al. Retroviral vectors containing a variant dihydrofolate reductase gene for drug protection and in vivo selection of hematopoietic cells. Stem Cells 1998;16:223-33.
194. Zhao SC, Banerjee D, Mineishi S, et al. Post-transplant methotrexate administration leads to improved curability of mice bearing a mammary tumor transplanted with marrow transduced with a mutant human dihydrofolate reductase cDNA. Hum Gene Ther 1997;8:903-9.
195. Kleibl K, Margison GP. Increasing DNA repair capacity in bone marrow by gene transfer as a prospective tool in cancer therapy. Neoplasma 1998;45:181-6.
196. Wang G, Weiss C, Sheng P, et al. Retrovirus-mediated transfer of the human O6-methylguanine-DNA methyltransferase gene into a murine hematopoietic stem cell line and resistance to the toxic effects of certain alkylating agents. Biochem Pharmacol 1996;51:1221-8.
197. Davis BM, Roth JC, Liu L, et al. Characterization of the P140K, PVP(138-140)MLK, and G156A O6-methylguanine-DNA methyltransferase mutants: Implications for drug resistance gene therapy. Hum Gene Ther 1999;10:2769-78.
198. Iwata M, Nunoi H, Matsuda I, et al. Drug-selected complete restoration of superoxide generation in Epstein-Barr virus-transformed B cells from p47phox-deficient chronic granulomatous disease patients by using a bicistronic retrovirus vector encoding a human multi-drug resistance gene (MDR1) and the p47phox gene. Hum Genet 1998;103:419-23.
199. Koc ON, Allay JA, Lee K, et al. Transfer of drug resistance genes into hematopoietic progenitors to improve chemotherapy tolerance. Semin Oncol 1996;23:46-65.
200. Denham DW, Franz MG, Denham W, et al. Directed antisense therapy confirms the role of protein kinase C-alpha in the tumorigenicity of pancreatic cancer. Surgery 1998;124:218-24.
201. Gazdar AF, Minna JD. Targeted therapies for killing tumor cells. Proc Natl Acad Sci USA 2001;98:10028-30.
202. Kijima H, Scanlon KJ. Ribozyme as an approach for growth suppression of human pancreatic cancer. Mol Biotechnol 2000;14:59-72.
203. Pohl U, Hohne MW, Gerlich WH, et al. Morphological and functional effects of antisense RNA to the deleted in colorectal carcinoma (DCC) gene in a pancreatic carcinoma cell line. Cancer Lett 1999;145:9-15.
204. Sharp PA. RNAi and double-strand RNA. Genes Dev 1999;13:139-41.
205. Tsuchida T, Kijima H, Hori S, et al. Adenovirus-mediated antiK-ras ribozyme induces apoptosis and growth suppression of human pancreatic carcinoma. Cancer Gene Ther 2000;7:373-83.
206. Wright L, Kearney P. Current status of ribozymes as gene therapy agents for cancer. Cancer Invest 2001;19:495-509.
207. Aoki K, Yoshida T, Sugimura T, et al. Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity. Cancer Res 1995;55:3810-6.
208. Aoki K, Yoshida T, Matsumoto N, et al. Gene therapy for peritoneal dissemination of pancreatic cancer by liposome-mediated transfer of herpes simplex virus thymidine kinase gene. Hum Gene Ther 1997;8:1105-13.
209. Shichinohe T, Senmaru N, Furuuchi K, et al. Suppression of pancreatic cancer by the dominant negative ras mutant, N116Y. J Surg Res 1996;66:125-30.
210. Takeuchi M, Shichinohe T, Senmaru N, et al. The dominant negative H-ras mutant, N116Y, suppresses growth of metastatic human pancreatic cancer cells in the liver of nude mice. Gene Ther 2000;7:518-26.
211. Moelling K, Strack B, Radziwill G. Signal transduction as target of gene therapy. Recent Results. Cancer Res 1996;142:63-71.
212. Bouvet M, Bold RJ, Lee J, et al. Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer. Ann Surg Oncol 1998;5:681-8.
213. Hwang RF, Gordon EM, Anderson WF, et al. Gene therapy for primary and metastatic pancreatic cancer with intraperitoneal retroviral vector bearing the wild-type p53 gene. Surgery 1998;124:143-51.
214. Rodicker F, Stiewe T, Zimmermann S, et al. Therapeutic efficacy of E2F1 in pancreatic cancer correlates with TP73 induction. Cancer Res 2001;61:7052-5.
215. Joshi US, Dergham ST, Chen YQ, et al. Inhibition of pancreatic tumor cell growth in culture by p21WAF1 recombinant adenovirus. Pancreas 1998;16:107-13.
216. Kobayashi S, Shirasawa H, Sashiyama H, et al. P16INK4a expression adenovirus vector to suppress pancreas cancer cell proliferation. Clin Cancer Res 1999;5:4182-5.
217. Ghaneh P, Greenhalf W, Humphreys M, et al. Adenovirus-mediated transfer of p53 and p16(INK4a) results in pancreatic cancer regression in vitro and in vivo. Gene Ther 2001;8:199-208.
218. Koul D, Parthasarathy R, Shen R, et al. Suppression of matrix metalloproteinase-2 gene expression and invasion in human glioma cells by MMAC/PTEN. Oncogene 2001;20:6669-78.
219. Barton CM, McKie AB, Hogg A, et al. Abnormalities of the RB1 and DCC tumor suppressor genes: Uncommon in human pancreatic adenocarcinoma. Mol Carcinog 1995;13:61-9.
220. Hohne MW, Halatsch ME, Kahl GF, et al. Frequent loss of expression of the potential tumor suppressor gene DCC in ductal pancreatic adenocarcinoma. Cancer Res 1992;52:2616-9.
221. Hilgers W, Song JJ, Haye M, et al. Homozygous deletions inactivate DCC, but not MADH4/DPC4/SMAD4, in a subset of pancreatic and biliary cancers. Genes Chromosomes Cancer 2000;27:353-7.
222. Buscail L, Esteve JP, Saint-Laurent N, et al. Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Natl Acad Sci USA 1995;92:1580-4.
223. Buscail L, Saint-Laurent N, Chastre E, et al. Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Res 1996;56:1823-7.
224. Benali N, Cordelier P, Calise D, et al. Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238. Proc Natl Acad Sci USA 2000;97:9180-5.
225. Su Z, Lebedeva IV, Gopalkrishnan RV, et al. A combinatorial approach for selectively inducing programmed cell death in human pancreatic cancer cells. Proc Natl Acad Sci USA 2001;98:10332-7.
226. Simon B, Bartsch D, Barth P, et al. Frequent abnormalities of the putative tumor suppressor gene FHIT at 3p14.2 in pancreatic carcinoma cell lines. Cancer Res 1998;58:1583-7.
227. Ishii H, Dumon KR, Vecchione A, et al. Potential cancer therapy with the fragile histidine triad gene: Review of the preclinical studies. JAMA 2001;286:2441-9.
228. Dumon KR, Ishii H, Vecchione A, et al. Fragile histidine triad expression delays tumor development and induces apoptosis in human pancreatic cancer. Cancer Res 2001;61:4827-36.
229. Cheng YC, Grill SP, Dutschman GE, et al. Metabolism of 9-(1,3-dihydroxy-2-propoxymethyl)guanine, a new anti herpes virus compound, in herpes simplex virus-infected cells. J Biol Chem 1983;258:12460-4.
230. Cheng YC, Huang ES, Lin JC, et al. Unique spectrum of activity of 9-[(1,3-dihydroxy-2-propoxy)methyl]-guanine against herpesviruses in vitro and its mode of action against herpes simplex virus type 1. Proc Natl Acad Sci USA 1983;80:2767-70.
231. Field AK, Davies ME, DeWitt C, et al. 9-([2-Hydroxy-1-(hydroxymethyl)ethoxy]methyl)-guanine: A selective inhibitor of herpes group virus replication. Proc Natl Acad Sci USA 1983;80:4139-43.
232. Elshami AA, Saavedra A, Zhang H, et al. Gap junctions play a role in the 'bystander effect' of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther 1996;3:85-92.
233. Fick J, Barker 2nd FG, Dazin P, et al. The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro. Proc Natl Acad Sci USA 1995;92:11071-5.
234. Mesnil M, Piccoli C, Tiraby G, et al. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci USA 1996;93:1831-5.
235. Block A, Chen SH, Kosai K, et al. Adenoviral-mediated herpes simplex virus thymidine kinase gene transfer: Regression of hepatic metastasis of pancreatic tumors. Pancreas 1997;15:25-34.
236. Makinen K, Loimas S, Wahlfors J, et al. Evaluation of herpes simplex thymidine kinase mediated gene therapy in experimental pancreatic cancer. J Gene Med 2000;2:361-7.
237. Rosenfeld ME, Vickers SM, Raben D, et al. Pancreatic carcinoma cell killing by way of adenoviral mediated delivery of the herpes simplex virus thymidine kinase gene. Ann Surg 1997;225:609-20.
238. Karle P, Muller P, Renz R, et al. Intratumoral injection of encapsulated cells producing an oxazaphosphorine activating cytochrome P450 for targeted chemotherapy. Adv Exp Med Biol 1998;451:97-106.
239. Lohr M, Hoffmeyer A, Kroger J, et al. Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma. Lancet 2001;357:1591-2.
240. Haack K, Linnebacher M, Eisold S, et al. Induction of protective immunity against syngeneic rat cancer cells by expression of the cytosine deaminase suicide gene. Cancer Gene Ther 2000;7:1357-64.
241. Ohashi M, Kanai F, Tanaka T, et al. In vivo adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing pancreatic cancer. Jpn J Cancer Res 1998;89:457-62.
242. Chiocca EA, Choi BB, Cai WZ, et al. Transfer and expression of the lacZ gene in rat brain neurons mediated by herpes simplex virus mutants. New Biol 1990;2:739-46.
243. Martuza RL. Conditionally replicating herpes vectors for cancer therapy. J Clin Invest 2000;105:841-6.
244. Miyatake S, Iyer A, Martuza RL, et al. Transcriptional targeting of herpes simplex virus for cell-specific replication. J Virol 1997;71:5124-32.
245. Todo T, Martuza RL, Rabkin SD, et al. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci USA 2001;98:6396-401.
246. Kasuya H, Mizuno M, Yoshida J, et al. Combined effects of adeno-associated virus vector and a herpes simplex virus mutant as neoplastic therapy. J Surg Oncol 2000;74:214-8.
247. Lee JH, Federoff HJ, Schoeniger LO. G207, modified herpes simplex virus type 1, kills human pancreatic cancer cells in vitro. J Gastrointest Surg 1999;3:127-33.
248. Stevenson AJ, Giles MS, Hall KT, et al. Specific oncolytic activity of herpesvirus saimiri in pancreatic cancer cells. Br J Cancer 2000;83:329-32.
249. DeWeese TL, van der Poel H, Li S, et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res 2001;61:7464-72.
250. Doronin K, Kuppuswamy M, Toth K, et al. Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy. J Virol 2001;75:3314-24.
251. Kurihara T, Brough DE, Kovesdi I, et al. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J Clin Invest 2000;106:763-71.
252. Steinwaerder DS, Carlson CA, Otto DL, et al. Tumor-specific gene expression in hepatic metastases by a replication-activated adenovirus vector. Nat Med 2001;7:240-3.
253. Heise C, Ganly I, Kim YT, et al. Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status. Gene Ther 2000;7:1925-9.
254. Vollmer CM, Ribas A, Butterfield LH, et al. p53 selective and nonselective replication of an E1B-deleted adenovirus in hepatocellular carcinoma. Cancer Res 1999;59:4369-74.
255. Khuri FR, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000;6:879-85.
256. Nemunaitis J, Ganly I, Khuri F, et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial. Cancer Res 2000;60:6359-66.
257. Mulvihill S, Warren R, Venook A, et al. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: A phase I trial. Gene Ther 2001;8:308-15.
258. Matsubara S, Wada Y, Gardner TA, et al. A conditional replication-competent adenoviral vector, Ad-OC-Ela, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis. Cancer Res 2001;61:6012-9.
259. McNeish IA, Green NK, Gilligan MG, et al. Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954. Gene Ther 1998;5:1061-9.